Certara, Inc. (CERT) Stock

Certara, Inc. is a leading provider of software products and technology-enabled services specializing in biosimulation across various stages of drug discovery, preclinical and clinical research, regulatory submissions, and market access.

The company plays a pivotal role in transforming drug development by offering advanced biosimulation software, technology, and services that facilitate the delivery of effective medicines to patients. Certara supports its clients throughout the entire drug development lifecycle, guiding new drug candidates through regulatory approvals and into commercialization. Its comprehensive suite of technology-enabled services includes mechanistic and empirical biosimulation, drug development strategies, clinical pharmacology, model-based meta-analysis, regulatory writing, medical communications, regulatory operations, and market access strategies.

Certara's robust software portfolio encompasses specialized platforms such as mechanistic biosimulation, PK/PD biosimulation, data standardization tools, scientific informatics, clinical outcomes databases, regulatory submission management, and market access communication platforms. Catering primarily to biopharmaceutical companies, academic institutions, and government entities, Certara operates globally with a presence in key markets across North America, Europe, Asia Pacific, and beyond. Founded in 2008 and headquartered in Princeton, New Jersey, Certara Inc. continues to lead innovation in biosimulation technologies aimed at advancing therapeutic discoveries and improving healthcare outcomes worldwide.